GO
Loading...

Enter multiple symbols separated by commas

Bayer AG

More

  • Bayer CEO: Agriculture Will Drive Profits   Thursday, 25 Apr 2013 | 6:05 AM ET
    Bayer CEO: Agriculture Will Drive Profits

    Marijn Dekkers, CEO of Bayer, says the positive outlook for 2013 is driven by strong projected strong growth in Healthcare and Crop Sciences and explains how the company is heavily investing in its growth.

  • What Now for Western Drugmakers in India? Tuesday, 2 Apr 2013 | 7:53 PM ET

    Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country with a market potential as large as India's.

  • Bayer CEO: Confident of Meeting Tough Targets   Thursday, 28 Feb 2013 | 6:30 AM ET
    Bayer CEO: Confident of Meeting Tough Targets

    Marijn Dekkers, CEO of Bayer, tells CNBC why the company's development of new drugs make him confident of reaching targets set of 2.5 billion euros in drug sales.

  • Syngenta Upbeat for Spring Planting Season Wednesday, 6 Feb 2013 | 2:20 AM ET
    agricultural_biotech_200.jpg

    Syngenta, the world's largest agrochemicals company, said it was confident ahead of the upcoming planting season and will hike its dividend 19 percent after it posted a full-year net profit that beat expectations.

  • Europe Stocks Close Higher; DAX at Multi-Year Highs Friday, 25 Jan 2013 | 11:40 AM ET
    Busch: This Global Game of Chicken Hurts Markets

    Weak GDP data for the U.K. wasn't enough to stop European shares rising on Friday as Germany's DAX Index reached a level not seen since January 2008 after business climate data was released.

  • Bayer CEO On Innovation vs. Affordable Drugs   Thursday, 24 Jan 2013 | 4:10 AM ET
    Bayer's Dekkers On  Innovation vs. Affordable Drugs

    Marijn Dekkers, CEO of Bayer, talks to CNBC about the outlook for the pharmaceutical industry

  • Drug Pipelines Begin to Fill For Big Pharma Sunday, 13 Jan 2013 | 4:30 PM ET
    pills.jpg

    The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.

  • Bayer Has Promising Product Pipeline: CEO   Wednesday, 14 Nov 2012 | 11:24 AM ET
    Bayer Has Promising Product Pipeline: CEO

    Marijn Dekkers, CEO of Bayer, explains to CNBC that while Bayer has felt increased pressure on drug pricing from governments, its success in research and development has the company positioned for success.

  • Bayer CEO Speaks on $1.2 Billion Deal   Tuesday, 30 Oct 2012 | 12:30 PM ET
    Bayer CEO Speaks on $1.2 Billion Deal

    Bayer CEO Marijn Dekkers says the firm's $1.2 billion purchase of Schiff Nutrition will help Bayer build its position in consumer healthcare.

  • RESEARCH ALERT-Cheuvreux cuts Bayer to outperform Friday, 12 Oct 2012 | 4:35 AM ET

    *Cheuvreux cuts Bayer to outperform from selected list. Reuters Station users, click. 1568. Reuters Station users, click. 4899.

  • *Jefferies cuts AstraZeneca PLC price target to 3,000 p from 3,100 p;. *Jefferies raises Bayer AG price target to 71 euros from 65 euros;. *Jefferies raises Eli Lilly price target to $36 from $35; rating.

  • FRANKFURT, Oct 9- Bayer AG:. *Says European commission gives green light for flexyess. *Says health authorities of the EU member states will grant national approvals.

  • Shares in CIMB Thai Bank Pcl jumped as much as 23 percent to 2.96 baht, the highest since Nov. 5, 2010, after a newspaper reported that its parent, CIMB Group Holdings Bhd, planned to buy a stake in Bank of Ayudhya.

  • German stocks - Factors to watch on October 3 Wednesday, 3 Oct 2012 | 1:17 AM ET

    DEUTSCHE TELEKOM Indicated 0.1 percent lower. Deutsche Telekom is in talks to merge its T-Mobile USA unit with smaller rival MetroPCS, in a move that could pave the way for the German company to eventually exit the U.S. wireless market.

  • U.S. finds no wrongdoing in Yasmin patent settlement Tuesday, 2 Oct 2012 | 12:06 AM ET

    WASHINGTON, Oct 2- U.S. antitrust regulators found no wrongdoing in a deal made four years ago between German drugmaker Bayer AG and a division of Teva Pharmaceuticals to end patent litigation over the popular Yasmin birth control pill.

  • Irene Tse, who headed the North America operations of the Chief Investment Office, told the firm she is resigning to focus on "entrepreneurial ventures," according to a memo on Monday from Chief Operating Officer Matt Zames, a copy of which was obtained by Reuters.

  • He will be based in London. Willett joins from Royal Bank of Scotland, where most recently he was chairman of corporate finance for Europe, the Middle East and Africa. A top Morgan Stanley broker, Jonathan Madrigano, who last year managed about $2 billion in client assets left the company's brokerage division on Friday to join J.P. Morgan Securities.

  • MOVES-StanChart, BlackRock, Lazard, Barclays Monday, 1 Oct 2012 | 10:14 AM ET

    The bank named Tom Willett as head of mergers and acquisitions, Europe. He will be based in London. Willett joins from Royal Bank of Scotland, where most recently he was chairman of corporate finance for Europe, the Middle East and Africa.

  • FRANKFURT, Oct 1- Evotec AG:. *Evotec and Bayer enter into multi-target alliance to fight endometriosis. up to approximately euro 580 million.

  • Secure but Still Challenged Monday, 10 Oct 2011 | 11:49 AM ET
    woman-office-board-room-200.jpg

    When we began planning our special report  "Women in Business," I was eager to learn about how women are really doing in the workplace. In short, many women are successful, powerful and well off, but progress in the professional world has stalled.